NEW YORK (360Dx) – Copenhagen-based BluSense Diagnostics is developing a test that may solve one of the most challenging issues in the accurate detection and measurement of Zika — false positives triggered by cross reactivity from closely related infectious diseases to Zika, such as dengue and chikungunya.

The company expects to complete the development of a dengue assay this year and launch it on a centrifugal microfluidic immunoassay platform early next year. Later in 2018, it plans to release a combination assay on the same platform that can differentiate dengue from Zika.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.